In this review:
Treatment of cancer-related anorexia/cachexia syndrome
Erlotinib vs carboplatin and gemcitabine in EGFR mutation-positive NSCLC
ARQ197 plus erlotinib for NSCLC
Folfirinox vs gemcitabine as first-line treatment for MPA
GSK2118436 active against melanoma br
Please login below to download this issue (PDF)